Thursday, December 19

Tag: apparatus

Bausch + Lomb CEO Brent Saunders Pays $35.35 Million for Cher’s Former Miami Beach Home
28Nov By adminNo Comments
World

Bausch + Lomb CEO Brent Saunders Pays $35.35 Million for Cher’s Former Miami Beach Home

By E.B. Solomont Nov. 28, 2023 1:25 pm ETListen to article(2 minutes)Bausch + Lomb CEO Brent Saunders has purchased Cher’s former waterfront home in Miami Beach, Fla., for $35.35 million.The La Gorce Island home, which Cher owned in the 1990s, hit the market three months ago for $42.5 million.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding
17Nov By adminNo Comments
Money

Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding

Updated Nov. 17, 2023 10:54 am ETThere is a bit of cognitive dissonance in healthcare investing right now.After reviewing the highly anticipated results from a study of Novo Nordisk’s blockbuster obesity treatment Wegovy released over the weekend, cardiologists at a major medical meeting and the pharma crowd on Wall Street were broadly upbeat. “Today’s confirmatory results lay the groundwork for the coming paradigm shift of metabolic treatment,” gushed Evan Seigerman, an analyst at BMO Capital Markets.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding
17Nov By adminNo Comments
World

Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding

There is a bit of cognitive dissonance in healthcare investing right now.After reviewing the highly anticipated results from a study of Novo Nordisk’s blockbuster obesity treatment Wegovy released over the weekend, cardiologists at a major medical meeting and the pharma crowd on Wall Street were broadly upbeat. “Today’s confirmatory results lay the groundwork for the coming paradigm shift of metabolic treatment,” gushed Evan Seigerman, an analyst at BMO Capital Markets.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Health Care Roundup: Market Talk
9Nov By adminNo Comments
World

Health Care Roundup: Market Talk

Updated Nov. 9, 2023 4:58 pm ETThe latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.1605 ET – US stocks close lower, snapping the S&P 500 and Nasdaq indexes’ longest winning streak in two years. Treasury yields and oil prices recovered some of their recent losses and the dollar strengthened. Chair Powell says the Fed doesn’t want to raise rates too high. Seed and pesticides maker Corteva slides 8% following Wednesday’s announcement it was closing one of its chemical facilities and halting operations in others to cut costs. Becton Dickinson falls 9% after the medical-device maker reported 2024 sales and earnings outlook that were below analysts’ expectations. DJIA loses 221 points to finish at 33892, whi...
Read More
LVMH to Buy Eyewear Brand Favored by the Stars
5Nov By adminNo Comments
World

LVMH to Buy Eyewear Brand Favored by the Stars

PARIS—LVMH Moët Hennessy Louis Vuitton has agreed to buy Los Angeles-based eyewear maker Barton Perreira, part of the luxury conglomerate’s push to extend its reach to goods with mass-market appeal. Eyewear has emerged in recent years as one of the first purchases that aspiring luxury consumers make before moving on to more expensive items such as handbags. That is prompting LVMH and other luxury-goods companies to wean themselves off licensing agreements with third-party manufacturers and develop in-house eyewear operations.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Health Care Roundup: Market Talk
3Nov By adminNo Comments
World

Health Care Roundup: Market Talk

Updated Nov. 3, 2023 12:28 pm ETThe latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.1005 ET – Smith & Nephew’s shares have fallen too far, JPMorgan says, upgrading the artificial-hip maker to overweight from neutral. The stock has dropped to 10-year lows in the last few weeks on factors such as concerns about a margin-guidance downgrade after lackluster first-half margins, JPM says. Still, stronger-than-expected third-quarter revenues are likely to build confidence that top-line growth is sustainable, JPM says. “The de-rating in our view is overdone and we believe investors are likely to revisit the investment case,” JPM analyst David Adlington writes, though the bank cuts its price target on the stock...
Read More
ViewRay Files for Bankruptcy, Plans to Pursue Sale
17Jul By adminNo Comments
World

ViewRay Files for Bankruptcy, Plans to Pursue Sale

ViewRay, which makes the MRIdian radiation-therapy system, said it has filed for bankruptcy and plans to sell some or all of its assets. The company said it has received a commitment of about $6 million in debtor-in-possession financing from MidCap Financial Services. That, along with existing liquidity, should be enough to support operations through the Chapter 11 process. The...
Read More